Drug Trial News

RSS

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate.

22 Jan 2013

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, has reported promising results with its lead program of antibody-drug conjugates (ADCs).

22 Jan 2013

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Dezima Pharma ('Dezima'), the biotechnology company developing innovative drugs in the field of dyslipidemia, announced today the in-licensing of a cholesteryl ester transfer protein (CETP) inhibitor DEZ-001 (formerly TA-8995) from Mitsubishi Tanabe Pharma Corporation (MTPC). Terms of the deal were not disclosed.

22 Jan 2013

Scientists figure out how to dodge HPV-triggered cancers by vaccination

In 2009, more than 30,000 people in the U.S. learned they had cancer linked to the human papillomavirus, or HPV. This virus is best known for causing cervical cancer, but it's also the culprit behind many cancers of the mouth, throat, anus, and genitals. Unlike many forms of cancer, for which we lack the knowledge and tools to prevent, scientists have figured out how to dodge HPV-triggered cancers — by HPV vaccination.

19 Jan 2013

Botulinum toxin A more effective than intralesional steroids in treating plantar fasciitis

Plantar fasciitis is the most frequent cause of chronic heel pain, leaving many sufferers unable to put their best foot forward for months at a time. Now a Mexican study suggests that physicians should turn to Botox rather than steroids to offer patients the fastest road to recovery.

18 Jan 2013

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Nature reports how "a potential breakthrough in the quest to prevent HIV and AIDS has collided with sensitivities about testing expensive drugs in poor parts of the world."

18 Jan 2013

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company's pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso.

18 Jan 2013

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company researching a new class of glycobiology-based therapies for a broad range of diseases, today announced that it has completed enrolling patients in its Phase 2 study of GMI-1070, its lead investigational drug candidate.

18 Jan 2013

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Emergent BioSolutions Inc. today announced the initiation of a Phase 2 clinical trial for NuThrax (Anthrax Vaccine Adsorbed with CPG 7909 Adjuvant), also known as AV7909, with the dosing of the first subject.

18 Jan 2013

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

A groundbreaking, international clinical trial of an iron chelation drug, deferiprone, to treat the rare and devastating neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN), began last month at the trial's only North American site, Children's Hospital & Research Center Oakland.

17 Jan 2013

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

BHR Pharma, LLC announced today that the SyNAPSe® Trial's independent Data and Safety Monitoring Board (DSMB) evaluated safety data from 803 randomized patients and determined that no issues exist; therefore, the trial may continue towards its intended completion.

17 Jan 2013

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Amgen today announced top-line results of the Phase 3 Aranesp (darbepoetin alfa) RED-HF (Reduction of Events With Darbepoetin Alfa in Heart Failure) Trial.

17 Jan 2013

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Reviva Pharmaceuticals, Inc., a privately held drug discovery and development company, today announces completion of patient enrollment in the phase 2 clinical trial of RP5063 for the treatment of schizophrenia and schizoaffective disorder.

16 Jan 2013

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Cytos Biotechnology Ltd today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma.

16 Jan 2013

Angiotensin II blockade does not seem to provide benefit to kidney transplant recipients

A drug that protects the kidneys of patients with chronic kidney disease does not seem to provide the same benefit to kidney transplant recipients, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

11 Jan 2013

Placing peanut protein under a patient's tongue helps dampen allergic reactions

Of all foods, peanuts are the most frequent cause of life-threatening and fatal allergic reactions. New research at National Jewish Health provides additional support for a strategy to reduce the severity of reactions to peanut- repeatedly consuming small amounts of the very food that causes those reactions in the first place, a practice called immunotherapy.

11 Jan 2013

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

Morphotek Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational agent farletuzumab (MORAb-003) in combination with carboplatin and a taxane in patients with platinum-sensitive epithelial ovarian cancer in first relapse.

11 Jan 2013

TapImmune announces results from HER2/neu interim study on breast cancer

TapImmune Inc. has announced that an interim safety analysis on the first five breast cancer patients treated with HER2/neu Class II antigens at Mayo Clinic, Rochester, MN., did not show any serious adverse events.

11 Jan 2013

Study compares three treatment approaches in membranous nephropathy

The results of a pioneering UK-wide clinical trial that compared treatments for patients with a common type of kidney disease has found one to be significantly more effective. The results of the study, published online in The Lancet, will be recommended to clinicians worldwide as the most effective approach to treating the condition.

10 Jan 2013

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, reports that the Moffitt Cancer Center has initiated a Phase 1 study to investigate potential immune biomarkers in both tumor tissue and peripheral blood after intralesional PV-10 injection of melanoma tumors.

9 Jan 2013

Drug Trial News

Dutasteride decreases risk of biopsy detectable prostate cancer by 22.8%

Synthon Biopharmaceuticals announces promising results with its antibody-drug conjugate program

Mitsubishi Tanabe Pharma in-licenses CETP inhibitor to Dezima Pharma

Scientists figure out how to dodge HPV-triggered cancers by vaccination

Botulinum toxin A more effective than intralesional steroids in treating plantar fasciitis

Researchers disagree over ethics of HIV treatment clinical trial in Africa, Nature reports

Boehringer Ingelheim initiates enrollment in Phase III IFN-free HCV trial

Enrollment complete in GlycoMimetics’ GMI-1070 Phase 2 study for sickle cell disease

Emergent BioSolutions commences NuThrax Phase 2 trial in anthrax infection

Children's Oakland recruits patients for deferiprone clinical trial to treat PKAN

SyNAPSe® Trial by BHR Pharma deemed to have no safety issues according to DSMB

Top-line results from Amgen’s Aranesp Phase 3 trial on heart failure and anemia

Reviva Pharmaceuticals completes enrollment in RP5063 phase 2 trial for schizophrenia

Update on Cytos’ CYT003 Phase 2b trial for allergic asthma

Angiotensin II blockade does not seem to provide benefit to kidney transplant recipients

Placing peanut protein under a patient's tongue helps dampen allergic reactions

Results from Morphotek’s farletuzumab Phase III combination study on ovarian cancer

TapImmune announces results from HER2/neu interim study on breast cancer

Study compares three treatment approaches in membranous nephropathy

Moffitt Cancer Center initiates PV-10 Phase 1 study in melanoma

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News